In a study of open-label Truvada as daily pre-exposure prophylaxis (PrEP) to prevent HIV among 427 young African women and adolescent girls, 95% initiated the HIV prevention strategy, and most used PrEP for the first three months. However, PrEP use fell among participants in this critical population during a year of follow-up clinic visits, although HIV incidence at 12 months was low. The preliminary results suggest that tailored, evidence-based adherence support strategies may be needed to durably engage young African women in consistent PrEP use.
UW Department of Global Health researchers presented new HIV prevention findings at the HIV Research for Prevention (HIVR4P 2018) conference in Madrid. HIVR4P is the only global scientific conference focused exclusively on the challenging and fast-growing field of biomedical HIV prevention research. The conference supports global cross-fertilization among research on HIV vaccines, microbicides, PrEP, treatment as prevention, and other biomedical prevention approaches.
By Gerard Gallagher
Oral pre-exposure prophylaxis, or PrEP, for HIV prevention has a similar efficacy in women with “abnormal” vs. “normal” vaginal microbiota, according to recent findings.
By Tony Kirby
"The last person that I train, I want that training to be in something other than HIV", says Jared Baeten. Speaking to The Lancet Infectious Diseases from the HIV Research for Prevention Conference (HIVR4P) in Chicago, IL, where he brought a 12-strong team of his researchers, Baeten explains: “When that time comes, I want HIV to have been eliminated as public health threat, so we can focus on other diseases”.
Study involves researchers with UW International Clinical Research Center
By Bobbi Nodell
Researchers have found that breastfeeding mothers taking the antiretroviral drugs tenofovir and emtricitabine have a low risk of side effects. The study, published in PLOS, was conducted by colleagues at the UW International Clinical Research Center and partners in Kenya, Uganda and Johns Hopkins University.
By Bruce Jancin
DURBAN, SOUTH AFRICA – Oral antiretroviral pre-exposure prophylaxis (PrEP) against HIV also reduces the risk of acquiring herpes simplex virus type 2, according to research presented at the 21st International AIDS Conference.
“Given the limited interventions for primary prevention of HSV-2, efficacy against HSV-2 provides additional benefit to oral PrEP,” observed Connie Celum, MD, professor of global health and medicine at the University of Washington, Seattle.
Researchers saw 95% fewer cases than expected; model offered antiretroviral meds to HIV-infected members and preventive therapy for uninfected partners
Providing HIV medication to both members of a HIV-serodiscordant couple substantially reduced the risk of transmission within that couple, according to a study published Aug. 23 in PLOS Medicine.
The University of Washington is one of 56 DREAMS Innovation Challenge winners* announced on Monday by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR); Janssen Pharmaceutica NV (Janssen), one of the Janssen pharmaceutical companies of Johnson & Johnson; and ViiV Healthcare.
By Lucy Tiven
On Tuesday, the Journal of the American Medical Association published a study on antiretroviral therapy (ART) and HIV transmission in mixed status couples — couples where one partner is HIV positive.